Medicine-Hematology and Medical Oncology
Academic Department
Affiliation
Research
administers grant
-
2024 Robert A. Winn Diversity In Clinical Trials: Career Development Award Agreement
-
A Program for Metastatic Breast Cancer Research
-
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
-
Autoimmune Stem-like CD8 T cells in Type I Diabetes
-
BLOSSoM (Building Leaders with Opportunities for Success in Science of the Meyer Cancer Center)
-
Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies
-
BioPharma Alliance Agreement- Janssen Research & Development
-
Bridging Gaps and Transforming CARE for Young Breast Cancer Survivors and those with Metastatic Disease
-
CD36 in breast cancer
-
Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV
-
Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving Frontline Treatment at Cancer Centers Within the LEO Cohort
-
Characterization of CDADC1, a Putative CTP Deaminase Co-deleted with RB1 in Bladder Cancer
-
Characterizing and targeting aberrant NOTCH1 signaling in Richter''s syndrome
-
Characterizing the Role and Targeting of the histone methyltransferase Setd2 in Multiple Myeloma
-
Characterizing the role of BCL10 somatic mutations in B cell lymphomas
-
Chromatin Remodeling Complexes as Drivers of Resistance in Acute Myeloid Leukemia
-
Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer.
-
Collaborative Subcontract with University of Texas M.D. Anderson Cancer Center and Dr. Melnick
-
Comprehensive Assessment of Cancer Theranostics Response
-
Controlling the Niche to Control Clonal Hematopoiesis
-
Correlative biomarkers to optimize breast cancer treatment and prevention strategies
-
DUA Study to Understand the Effectiveness of EpkinlyTM (epcoritamab-bysp) in the Real World
-
Define genetically/epigenetically modified targets in the immune niche of DLBCLs- Project 2
-
Define the evolutionary trajectories of CLL undergoing Richter transformation through single-cell multi-omics
-
Defining the epigenetic landscape and therapeutic vulnerabilities of Richter''s syndrome in CRISPR-based mouse models
-
Defining the impact of Kras mutational heterogeneity on the tumor microenvironment in pancreatic cancer
-
Determinants Of The Racial/Ethnic Disparity In MGUS Risk: An Epidemiologic Study In 4 Cohorts
-
Development and optimization of CEACAM5-targeted alpha emitters
-
Development of Small Molecule therapeutics targeting AR-V7 for prostate cancer.
-
Development of a platform for high throughput drug screening on CTC-derived organoid in breast and colorectal cancer
-
Directing Fate, Subtype Identity And Survival In Human Pluripotent-Derived Midbrain Dopamine Neurons
-
Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
-
Dissect MGA-mutant lymphomagenesis towards novel rational therapeutics for DLBCL and Richter transformation.
-
Dysregulated mechanoimmunology of epigenetics-driven lymphomas
-
Early detection blood test for universal breast cancer screening to improve early diagnosis for women of all social and ethnic backgrounds
-
Early intervention for the prevention of blood cancer development.
-
Effects of tumor energetics on anti-tumor immunity through vasculature remodeling
-
Elucidating Metabolic Pathways Regulating Germinal Center B Cells And Derived Lymphomas
-
Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma
-
Enhancing the Efficacy of Docetaxel in Prostate Cancer
-
Epigenetic basis and therapeutic interdiction of FL progression
-
Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
-
Exploiting tumor metabolism to optimize T cell therapy
-
Exploiting tumor metabolism to optimize T cell therapy
-
First-in-Class Dual AR-V7/AR-fl Molecular Glue Degrader for Prostate Cancer Treatment
-
Functionally active ecDNA in African Americans drives oncogenic pathways forming therapeutic targets
-
Germline-somatic interactions as drivers and therapeutic targets in bladder cancer
-
Germline-somatic interactions as drivers and therapeutic targets in bladder cancer
-
Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab
-
Higher burden of extrachromosomal DNA amplifications drives worse clinical outcomes in African American bladder cancer patients
-
How the immune system becomes malignant
-
Identifying B cell developmental changes and therapeutic vulnerabilities of MGA-mutant Richter''s syndrome
-
Identifying Mechanisms of Response, Resistance and Toxicity to BCMA CAR T Therapy in Multiple Myeloma
-
Immune Tolerance Network
-
Immunomodulatory Ligand B7-1 Targets p75 Neurotrophin Receptor in Neurodegeneration
-
Inhibiting EZH2 to improve CAR T immunotherapy in B-cell lymphomas
-
Investigating the tumor metabolism-hypoxia-vasculature axis in the response of TNBC to immunotherapy
-
Janssen Biopharma Agreement
-
Liquid biopsy to decipher lobular breast cancer metastatic spread
-
Lorenzo Foffano American-Italian Cancer Foundation (AICF) for the period 2025-2026
-
Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling in Human Lymphomas
-
MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL
-
Measuring Myeloproliferative Neoplasms Stem and Progenitor Cell Clonal Fitness to predict disease outcome
-
Measuring and directing cellular age in cortical neurons and glial cells in models of Alzheimer''s'' disease
-
Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunity
-
Metabolic and Inflammatory Response to a Whole Food Plant-Based Diet in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Phase II Randomized Study
-
Modeling Imetelstat Response in Bladder Cancer Organoid and PDX Models
-
Modulation of the Epigenome to Enhance CART Therapy against Non-Hodgkin Lymphoma
-
Molecular Mechanisms of eIF4E mediated transformation
-
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
-
Mutational and Aging Risk Factors for Myelodysplastic Syndrome
-
Myeloproliferative Neoplasms-Research Consortium
-
NRG Oncology Network Group Operations Center
-
Optimization Of Urinary DNA Deep Sequencing Tests To Enhance Clinical Staging Of Bladder Cancer Patients
-
Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
-
Optimization of strategies to improve NCI-sponsored clinical trial participation throughout the Weill Cornell Medicine - Meyer Cancer Center Sphere
-
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
-
Precision epigenetic therapy for SETD2+/- B cell lymphomas
-
Precision translation of therapeutic regimens for follicular lymphoma
-
Predicting risk of disease progression in polycythemia vera (PV): development and validation of a highly predictive dynamic model using machine learning and rich data from automated extraction of medical records and a novel informatics pipeline
-
Preemptive Rituximab for the Prevention of PTLD in EBV-Positive Solid Organ Transplant Recipients
-
Preventing follicular lymphoma progression and transformation through precision therapy
-
Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic Targeting
-
RCA with Montage Bio, Inc.
-
Research Collaboration Agreement- Treeline Biosciences, Inc.
-
Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy.
-
Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies
-
Role of MASP-2 in microvascular endothelial cell injury associated with severe COVID-19 and all HSCT-TMAs
-
Role of chromatin remodeling complex BAF in immunity and lymphoma
-
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
-
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
-
SETD2 and H1 Project
-
Sensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte Therapy
-
Sensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte Therapy
-
Sponsor Research Agreement with Dr. Abu-Zeinah and Pharma&
-
Sumitomo Dainippon Pharma Oncology, Inc - SRA
-
TOX-driven CD8 T cell differentiation and dysfunction in tumors
-
Targeted Therapies
-
Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer
-
Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
-
Targeting Epigenetic Circuits in B-Cell Lymphomas
-
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
-
Targeting Unmet Needs For B-cell Lymphomas
-
Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
-
Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
-
Targeting ecDNA to reverse therapy-resistance in urothelial cancer.
-
Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL
-
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
-
The National Cord Blood Network, National Chair
-
The National Cord Blood Network, National Chair
-
The National Cord Blood Network, Participating Center
-
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
-
The Role of SPEN as Tumor Suppressor in BN2 DLBCL
-
The association of HER2 expression on circulating tumor cells with the response to cyclin-dependent kinase 4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer
-
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
-
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
-
The role of SPEN and NOTCH2 mutations in pathogenesis of DLBCL.
-
Therapeutic Targeting of SIRT3 for Aggressive and Refractory Lymphomas
-
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
-
Translating molecular profiles into treatment approaches to target disparities in lymphoma
-
Uncovering MGA-driven epigenetic reprogramming in Richter''s syndrome
-
Uncovering immune evasion mechanisms and therapeutic targets in B-cell lymphomas via macrophage reprogramming
-
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
-
University of Pittsburgh - Weill Cornell Services Agreement - PRESENCE Study
-
Winn CDA Contact for Dr. Rohit Jain